At the Healthcare Business Headquarters of FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto), Takeda Pharmaceutical Company Limited (Headquarters: Chuo-ku, Osaka, hereinafter "Takeda Pharmaceutical") and Iwate Medical University (Headquarters: Chuo-ku, Osaka) Together with Yahaba Town, Morioka City, Iwate Prefecture, President: Kenji Sobue), we have started joint research on the diagnosis and treatment of Parkinson's disease using AI and genome (genetic information).

Parkinson's disease is a disease in which movement of the body is impaired due to abnormalities in the brain.One of the characteristics is that the appearance of symptoms and the rate at which the condition progresses after the onset of symptoms vary greatly from person to person.Most of the patients are elderly, but even young people can develop the disease, and the number of patients is currently said to be about 15 in Japan.

The purpose of this joint research is to realize medication and treatment tailored to the symptoms of each patient.In the research, we will analyze the information recorded in electronic medical records etc. through natural language processing by AI and verify the classification of symptoms and the effectiveness of treatment by multiplying it with the genome etc. of each patient. ..The research period of this case is two years, and while looking at the results, we will explore the possibility of practical application to actual diagnosis and treatment.

The roles of Iwate Medical University, Takeda Pharmaceutical, and FRONTEO in joint research are as follows.

Iwate Medical University:
Collection and provision of clinical information samples regarding Parkinson's disease (patient's personal information is processed)

Takeda:
Identify patient type and symptom appearance by preprocessing and analysis of genomic information, subgroup correlation analysis, etc.

FRONTEO:
Analyze natural sentences such as records of patient behaviors and remarks during interviews, findings and instructions of doctors and nurses, and identify patient types and symptoms.

Parkinson's disease has various symptoms such as tremors, difficulty in moving limbs, and slow movement, and the patient type varies from person to person.It is said that veteran specialists can understand future patterns of medical conditions from the statements and appearances of patients when they first see the doctor, but until now, it has been possible to share the knowledge of specialists and quantify the medical conditions. It has been considered difficult.

FRONTEO is an analysis using the artificial intelligence engine "Concept Encoder" (Concept Encoder, Patent No. 6346367), which is uniquely developed for the healthcare industry and features "objectiveness," "transparency," and "reproducibility." By clarifying important basic information related to disease diagnosis, we will carry out detailed classification and acquisition of information to promote this research.

In addition, Parkinson's disease is said to be able to improve symptoms or slow down the progression of Parkinson's disease by taking appropriate medication from an untreated state.By creating a route to utilize the analysis results based on Takeda's genomic information together, we will provide appropriate medication and treatment faster, realize personalized medicine tailored to each patient, and unmet medical.・ We would like to contribute to the improvement of Parkinson's disease, which is considered to be a need (there is no effective treatment).The impact of this matter on the Company's business results from the current fiscal year onward will be minor.

【concept encoderabout】URL: https://www.fronteo-healthcare.com/conceptencoder

Concept Encoder is an artificial intelligence (AI) developed by FRONTEO specifically for the healthcare industry.It was developed in 2018 with the aim of effectively analyzing and utilizing big data related to healthcare, which includes a large amount of free-form text data, based on evidence.We have introduced and realized statistical methods such as the significance test, which is indispensable for "evidence-based medicine (EBM)", which is a common understanding among healthcare professionals, in natural language analysis. Concept Encoder can also be co-analyzed with data other than text, and we are conducting research on co-analysis with "numerical data" such as gene expression information, vitals and various test values ​​accumulated in the healthcare field.Patent registration number: Patent No. XNUMX

【FRONTEOabout】URL: https://www.fronteo.com/

FRONTEO Co., Ltd. is a data analysis company that supports the analysis of information such as big data using its proprietary artificial intelligence engine "KIBIT".Established in August 2003 as a company that supports e-discovery (electronic discovery), which preserves, investigates, and analyzes electronic data necessary for international litigation, and digital forensic investigations.Proceeds against companies by making full use of in-house developed data analysis platform "Lit i View" and "Predictive Coding" technology that supports multiple languages ​​of Japanese, Chinese, Korean, and English. We provide countermeasure support.Unique artificial intelligence-related technologies such as "KIBIT" cultivated and developed in this legal tech AI business learn "tacit knowledge" such as expert experience and intuition, and analyze human thoughts to the future. Realize the prediction of behavior.We are developing the AI ​​solution business in areas such as business intelligence and healthcare, and have achieved results in "work style reform" in addition to FinTech and RegTech. In October 8, we will absorb the subsidiary FRONTEO Healthcare and work together to promote the use of Concept Encoder. Listed on TSE Mothers on June 2019, 10 and NASDAQ on May 2007, 6.The capital is 26 thousand yen (as of March 2013, 5). As of July 16, 2,559,206, the company name has been changed from UBIC Co., Ltd. to the current company name.